SCHEMBL4523312

SCHEMBL4523312

C=CCOc1ccc(CCl)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.40
ALDH1A1 P00352 10/20 0.39
CYP2D6 P10635 2/20 0.39
KDM4E B2RXH2 5/20 0.39
HPGD P15428 3/20 0.39
MAPT P10636 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
HTT P42858 1/20 0.38
HTR2A P28223 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3065052 0.87 MAPT (0.41) GAATSHRLMNAALDH1A1CYP2D6
SCHEMBL4879810 0.82 ALDH1A1 (0.56) GAALMNAALDH1A1CYP2D6KDM4E
SCHEMBL2523355 0.81 GAA (0.45) GAATSHRLMNAALDH1A1HPGD
SCHEMBL27628630 0.81 TTR (0.39) KDM4EL3MBTL1SMN1; SMN2
SCHEMBL28101685 0.81 LMNA (0.41) GAATSHRLMNAALDH1A1CYP2D6
SCHEMBL13777342 0.79 TSHR (0.58) GAATSHRLMNAALDH1A1KDM4E
SCHEMBL8161827 0.79 SMN1; SMN2 (0.45) GAATSHRLMNAALDH1A1KDM4E
SCHEMBL30401497 0.79 ALDH1A1 (0.42) GAATSHRLMNAALDH1A1KDM4E
SCHEMBL9495861 0.78 ALDH1A1 (0.39) GAATSHRLMNAALDH1A1CYP2D6
SCHEMBL3069648 0.78 ADRA2A (0.42) GAATSHRLMNAALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264485-A1 Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 US disclosed
US-7432291-B2 Ether derivatives HOFFMAN-LA ROCHE INC. (US) 2008-10-07 US disclosed
EP-1761525-B1 THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2008-07-23 EP disclosed
CN-101208335-A Pyrazole derivatives, their manufacture and their use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-06-25 CN disclosed
EP-1915370-A1 PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-04-30 EP disclosed
EP-1727815-B1 ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2007-06-27 EP disclosed
CN-1950366-A Thioether derivatives, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-04-18 CN disclosed
EP-1761525-A1 THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP disclosed
CN-1930154-A Ether derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-03-14 CN disclosed
WO-2007017222-A1 PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-15 WO disclosed
EP-1727815-A1 ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-12-06 EP disclosed
US-7005526-B2 Thioether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-02-28 US disclosed
WO-2005116019-A1 THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-08 WO disclosed
US-20050267179-A1 NOVEL THIOETHER DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-12-01 US disclosed
WO-2005090338-A1 ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-09-29 WO disclosed
US-20050209290-A1 Novel ether derivatives F. HOFFMAN-LA ROCHE AG (CH) 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267179-A1 NOVEL THIOETHER DERIVATIVES TPMT, TST, SULT1E1 GAA 1699/4885TSHR 492/4885LMNA 4338/4885
US-20090264485-A1 Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents CYP3A5, CYP3A43, CYP3A7 GAA 1984/4885TSHR 3130/4885LMNA 3120/4885
US-20050209290-A1 Novel ether derivatives CYP2E1, CYP11B1, CYP11B2 GAA 2171/4885TSHR 4019/4885LMNA 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.